 |
(Photo= Yonhap news) |
[Alpha Biz= Reporter Kim Jisun] Samsung Biologics announced on the 8th that it has signed a contract worth more than 250 billion won with the major U.S. pharmaceutical company Eli Lilly. As a result, the company's cumulative order amount for this year reached 885.5 billion won.
According to Samsung Biologics, the company increased the size of its existing contract with Eli Lilly from 3.278 trillion won to 5.84 trillion won, an increase of 2.562 trillion won.
Initially, when the contract was first announced in March 2022, the initial contract size was 1.122 trillion won (approximately 920.4 million dollars). Since then, it was increased by approximately 215.5 billion won to 3.278 trillion won in March last year, and then further increased to 5.84 trillion won this year.
Earlier, Eli Lilly drove its overall sales with sales of the obesity treatment drug recording sales of $517.4 million (approximately 706.9 billion won) in the first quarter alone.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
